Literature DB >> 318990

Heparin Therapy: regimens and management.

D Deykin.   

Abstract

Heparin remains the most effective antithrombotic drug. It acts by combining with plasma antithrombin, thereby accelerating the neurtalisation of thrombin and other acitvated coagulation factors. Full-dose intravenous heparin is indicated in all cases of pulmonary embolism and established deep venous thrombosis, unless there exist compelling contraindications. Continuous intravenous infusion of heparin appears to be safer than intermittent injection. Low-dose subcutaneous heparin is effective in preventing the initial occurrence of thigh vein thrombi and in reducing the incidence of fatal pulmonary embolism in general surgical patients over the age of 40. The efficacy of low-dose heparin in preventing pulmonary emboli following hip surgery has not been established. The incidence of severe heparin-induced thrombocytopenia appears to be rising. Platelet counts should be performed in all patients receiving heparin by any mode of administration.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 318990     DOI: 10.2165/00003495-197713010-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  14 in total

1.  Management of heparin therapy: Controlled prospective trial.

Authors:  E W Salzman; D Deykin; R M Shapiro; R Rosenberg
Journal:  N Engl J Med       Date:  1975-05-15       Impact factor: 91.245

2.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

3.  Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients.

Authors:  W R Bell; P A Tomasulo; B M Alving; T P Duffy
Journal:  Ann Intern Med       Date:  1976-08       Impact factor: 25.391

4.  Heparin-induced immune thrombocytopenia.

Authors:  R B Babcock; C W Dumper; W B Scharfman
Journal:  N Engl J Med       Date:  1976-07-29       Impact factor: 91.245

5.  The purification and mechanism of action of human antithrombin-heparin cofactor.

Authors:  R D Rosenberg; P S Damus
Journal:  J Biol Chem       Date:  1973-09-25       Impact factor: 5.157

6.  In vitro detection of platelet antibody in patients with idiopathic thrombocytopenic purpura and systemic lupus erythematosus.

Authors:  S Karpatkin; G W Siskind
Journal:  Blood       Date:  1969-06       Impact factor: 22.113

7.  Biological properties of the naturally occurring plasma inhibitor to activated factor X.

Authors:  E T Yin; S Wessler; P J Stoll
Journal:  J Biol Chem       Date:  1971-06-10       Impact factor: 5.157

8.  The assessment of drug-dependent and isoimmune antiplatelet antibodies by the use of platelet aggregometry.

Authors:  D Deykin; L J Hellerstein
Journal:  J Clin Invest       Date:  1972-12       Impact factor: 14.808

9.  Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement.

Authors:  S Sagar; D Nairn; J D Stamatakis; F H Maffei; A F Higgins; D P Thomas; V V Kakkar
Journal:  Lancet       Date:  1976-05-29       Impact factor: 79.321

Review 10.  Prevention of venous thromboembolism.

Authors:  A S Gallus; J Hirsh
Journal:  Semin Thromb Hemost       Date:  1976-04       Impact factor: 4.180

View more
  1 in total

1.  The quantitative reduction by heparin of intravenous thrombosis in normal and hypercoagulable animals.

Authors:  S M Lavelle; M Maclomhair
Journal:  Ir J Med Sci       Date:  1980-07       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.